NASDAQ:AIMTAimmune Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aimmune Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.61 -0.39 (-2.29 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$15.95Now: $16.61▼$16.9550-Day Range$15.24MA: $16.80▼$18.4252-Week Range$10.09Now: $16.61▼$37.00Volume1.15 million shsAverage Volume983,321 shsMarket Capitalization$1.08 billionP/E RatioN/ADividend YieldN/ABeta1 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingAimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.55, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.09, Aimmune Therapeutics has a potential upside of 141.4% from its current price of $16.61.Amount of Analyst CoverageAimmune Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesAimmune Therapeutics has received 463 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAimmune Therapeutics has received 314 “underperform” votes. (Add your “underperform” vote.)Community SentimentAimmune Therapeutics has received 59.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote “Outperform” if you believe AIMT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAimmune Therapeutics does not currently pay a dividend.Dividend GrowthAimmune Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aimmune Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,650,792.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 13.75% of the stock of Aimmune Therapeutics is held by insiders.Percentage Held by Institutions71.82% of the stock of Aimmune Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aimmune Therapeutics are expected to grow in the coming year, from ($4.41) to ($2.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aimmune Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aimmune Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAimmune Therapeutics has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A CIK1631650 Webwww.aimmune.com Phone650-614-5220Debt Debt-to-Equity Ratio0.59 Current Ratio8.10 Quick Ratio8.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.60 per share Price / Book4.61Profitability EPS (Most Recent Fiscal Year)($3.97) Net Income$-248,500,000.00 Net MarginsN/A Return on Equity-155.39% Return on Assets-92.41%Miscellaneous Employees228 Outstanding Shares65,250,000Market Cap$1.08 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:AIMT Rates by TradingView Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions How has Aimmune Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Aimmune Therapeutics' stock was trading at $17.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AIMT stock has decreased by 5.5% and is now trading at $16.61. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aimmune Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aimmune Therapeutics. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aimmune Therapeutics. How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) released its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by $0.16. The biotechnology company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.34 million. The firm's quarterly revenue was up NaN% on a year-over-year basis. During the same quarter last year, the business posted ($0.87) earnings per share. View Aimmune Therapeutics' earnings history. What price target have analysts set for AIMT? 11 brokers have issued 12 month target prices for Aimmune Therapeutics' stock. Their forecasts range from $15.00 to $66.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $40.09 in the next year. This suggests a possible upside of 141.4% from the stock's current price. View analysts' price targets for Aimmune Therapeutics. Has Aimmune Therapeutics been receiving favorable news coverage? Media stories about AIMT stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAimmune Therapeutics. Are investors shorting Aimmune Therapeutics? Aimmune Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 17,620,000 shares, an increase of 6.5% from the April 30th total of 16,550,000 shares. Based on an average trading volume of 1,500,000 shares, the short-interest ratio is presently 11.7 days. Currently, 39.4% of the company's stock are short sold. View Aimmune Therapeutics' Current Options Chain. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Zai Lab (ZLAB), Nektar Therapeutics (NKTR), PPD (SDGR), GW Pharmaceuticals PLC- (GWPH), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Allakos (ALLK), Biohaven Pharmaceutical (BHVN) and Arrowhead Pharmaceuticals (ARWR). View all competitors. What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Roku (ROKU). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the following people: Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)Dr. Stephen George Dilly, Special Advisor (Age 59)Dr. Daniel C. Adelman, Chief Medical Officer (Age 62) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO. What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." Who are Aimmune Therapeutics' major shareholders? Aimmune Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (5.90%), BlackRock Inc. (5.57%), State Street Corp (3.37%), Victory Capital Management Inc. (2.89%), Victory Capital Management Inc. (2.89%) and Fiera Capital Corp (2.47%). Company insiders that own Aimmune Therapeutics stock include Andrew Oxtoby, Daniel C Md Adelman, Des Produits Nestle S Societe, Douglas T Sheehy, Eric Bjerkholt, Health Science Us Holdi Nestle, Jayson Donald Alexander Dallas, Patrick G Enright and Stephen George Dilly. View institutional ownership trends for Aimmune Therapeutics. Which major investors are selling Aimmune Therapeutics stock? AIMT stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Wellington Management Group LLP, Bank of New York Mellon Corp, Victory Capital Management Inc., Victory Capital Management Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, and Fiera Capital Corp. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, and Douglas T Sheehy. View insider buying and selling activity for Aimmune Therapeutics. Which major investors are buying Aimmune Therapeutics stock? AIMT stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, Rice Hall James & Associates LLC, Balyasny Asset Management LLC, Burrage Capital Management LLC, and Pictet Asset Management Ltd.. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Andrew Oxtoby, Des Produits Nestle S Societe, Eric Bjerkholt, Health Science Us Holdi Nestle, Jayson Donald Alexander Dallas, and Patrick G Enright. View insider buying and selling activity for Aimmune Therapeutics. How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $16.61. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $1.08 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is www.aimmune.com. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
